RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Australia Channel

subscribe to Australia newsletter
Healthcare : Australia

   EMAIL   |   PRINT
Gardasil to be available in Australia by the end of 2006

Jun 10, 2006 - 1:35:00 PM , Reviewed by: Priya Saxena
Technology developed by Australian of the Year Professor Ian Frazer and his team from The University of Queensland helped create the preventative vaccine.

 
[RxPG] The world's first cervical cancer vaccine has been approved in the United States and could be on the shelves in Australia by the end of the year.

It will be a lifesaver for many women as cervical cancer kills about 270,000 women worldwide each year. Technology developed by Australian of the Year Professor Ian Frazer and his team from The University of Queensland helped create the preventative vaccine.

America's Food and Drug Administration has licensed the vaccine, Gardasil, for use in girls and women ages nine to 26. The vaccine protects against four of the dozens of strains of the human papillomavirus (HPV), which causes genital warts as well as cervical cancer.

US drugmaker Merck & Co. expects to start selling a three-shot series of Gardasil by the end of the month for about $485. Merck is seeking similar approval around the world including Australia, and approval in Australia is expected by next month.

"It is extremely exciting after 15 years to see the product finally reach the point where it will come to market," Professor Frazer said. "More gratifying still is the fact that women across the world will benefit significantly from this vaccine."

HPV causes abnormal cells or tissue growth on the feet, hands, vocal cords, mouth and genitals. About 60 types of HPV have been identified so far with each strand infecting certain parts of the body.



Publication: University of Queensland
On the web: www.researchaustralia.com.au 

Advertise in this space for $10 per month. Contact us today.


Related Australia News
Tourist dies of mosquito-borne virus in Australia
Indian-origin couple banned from running nursing homes in Australia
Gardasil to be available in Australia by the end of 2006
Plump Australian kids urged to get out more
"Take Panic Out of Bird Flu Pandemic"
Involve GPs in Frontline Response To Possible Flu Pandemic
AMA Urges Paroxetine Users To Consult Their Doctors
World No Tobacco Day Puts Health Professionals in the Spotlight
Health System Review Must Be Based on the Medical Model, Not the Economic Model
AMA Proposes Better Health Care for Refugees

Subscribe to Australia Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)